0 y) U/ Q" a$ s; [4 Y$ H临床上有依维莫司联合EGFR TKI作为易/特耐药之后的方案的研究:- z) C, Z- P' e/ F* r$ Y/ p# q
Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.$ u4 z" E- U) N6 m; m t http://www.ncbi.nlm.nih.gov/pubmed/22968184! ?2 O& N- B, o w4 t